D
Diane Tseng
Researcher at Stanford University
Publications - 24
Citations - 3088
Diane Tseng is an academic researcher from Stanford University. The author has contributed to research in topics: Antigen & Graft-versus-host disease. The author has an hindex of 13, co-authored 20 publications receiving 2335 citations. Previous affiliations of Diane Tseng include Harvard University.
Papers
More filters
Journal ArticleDOI
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham,Jens Peter Volkmer,Andrew J. Gentles,Debashis Sahoo,Piero Dalerba,Siddhartha Mitra,Jian Wang,Humberto Contreras-Trujillo,Robin Martin,Justin D. Cohen,Patricia Lovelace,Ferenc A. Scheeren,Mark P. Chao,Kipp Weiskopf,Chad Tang,Anne Kathrin Volkmer,Tejaswitha J. Naik,Theresa A. Storm,Adriane Mosley,Badreddin Edris,Seraina Schmid,Chris K. Sun,Mei-Sze Chua,Oihana Murillo,Pradeep S. Rajendran,Adriel C. Cha,Robert K. Chin,Dongkyoon Kim,Maddalena Adorno,Tal Raveh,Diane Tseng,Siddhartha Jaiswal,Per Øyvind Enger,Gary K. Steinberg,Gordon Li,Samuel So,Ravindra Majeti,Griffith R. Harsh,Matt De Van Rijn,Nelson N.H. Teng,John B. Sunwoo,Ash A. Alizadeh,Michael F. Clarke,Irving L. Weissman +43 more
TL;DR: All human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination, showing that CD47 is a commonly expressed molecule on all cancers, its function to blockphagocytosis is known, and blockade of its function leads to tumor cell phagcytosis and elimination.
Journal ArticleDOI
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.
Diane Tseng,Jens-Peter Volkmer,Stephen B. Willingham,Humberto Contreras-Trujillo,John W. Fathman,Nathaniel B. Fernhoff,Jun Seita,Matthew A. Inlay,Kipp Weiskopf,Masanori Miyanishi,Irving L. Weissman +10 more
TL;DR: It is shown that anti-CD47 antibody treatment not only enables macrophage phagocytosis of cancer but also can initiate an antitumor cytotoxic T-cell immune response.
Journal ArticleDOI
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment
TL;DR: This study examined whether neutralizing CD11b monoclonal antibodies could inhibit the recruitment of myeloid cells into irradiated tumors and inhibit their regrowth and supported the rationale of using clinically available Mac-1 (CD11b/CD18) antibodies as an adjuvant therapy to radiotherapy.
Journal ArticleDOI
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
Justin F. Gainor,Diane Tseng,Satoshi Yoda,Ibiayi Dagogo-Jack,Luc Friboulet,Jessica J. Lin,Harper Hubbeling,Leila Dardaei,Anna F. Farago,Katherine Schultz,Lorin A. Ferris,Zofia Piotrowska,James S. Hardwick,Donghui Huang,Mari Mino-Kenudson,A. John Iafrate,Aaron N. Hata,Beow Y. Yeap,Alice T. Shaw +18 more
TL;DR: ROS1 resistance mutations, particularly G2032R, appear to be the predominant mechanism of resistance to crizotinib, underscoring the need to develop novel ROS1 inhibitors with activity against these resistant mutants.
Journal ArticleDOI
Cancer stem cell-directed therapies: recent data from the laboratory and clinic.
TL;DR: Recent studies that demonstrate the utility of CSC-directed therapies are highlighted and the implications of the CSC hypothesis to experimental design and therapeutic strategies are discussed.